Introduction
There are multiple databases worldwide used to assess reported adverse events and serious adverse events (SAEs) after vaccination. The US VAERS database 1 is open for data reports by members of the public and community health care workers. A database was designed in Microsoft ACCESS to permit independent assessment by two reviewers of all data in reports of SAEs following yellow fever vaccination. The official criteria for assessing SAEs after yellow fever vaccination are those of the Brighton Collaboration 2-5 and these criteria are assessed in a series of panels. The ACCESS database uses panels to organize variables based on logic and entry workflows.
Summary of Figures
This panel is used to gather general demographic and admission data regarding a case, as well as references to the original publication ( Figure 1 ). Fields in the Summary panel include: country, sex, age, vaccine, vaccine type, batch number, days until first symptoms, if admitted to hospital, days in hospital, if died, and publication details. 
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Figure 4 Acute disseminated encephalomyelitis (ADEM)
Classified by Brighton Collaboration Levels 1, 2, and 3 of diagnostic certainty. Fields include demyelination on histopathology, magnetic resonance imaging (MRI) white matter lesions, monophasic illness, and nine clinical signs or symptoms ( Figure 4 ).
Figure 5 Viscerotropic disease
Viscerotropic disease is assessed in Figures 5 and 6. The case definition is classified by Brighton Collaboration Levels 1, 2, and 3 of diagnostic certainty and does not imply causality by yellow fever vaccine. Seven major and seven minor criteria are entered then the level is assessed ( Figure 5 ).
Figure 6 Yellow fever vaccineassociated viscerotropic disease
A second level of classification assigns levels of possible causality into "confirmed", "probable", and "suspect" levels. This permits differentiation between cases caused by wild yellow fever virus and by yellow fever vaccine. The case meets the suspect level if the individual had been in a yellow fever-endemic or -epidemic area within 10 days of onset of symptoms and yellow fever virusspecific antigen was detected in tissue demonstrated by immunohistochemistry or histopathology consistent with yellow fever. It meets the probable and definite levels if it meets the suspect level and yellow fever 17D virus is demonstrated within specific time periods or at specific concentrations ( Figure 6 ).
Figure 7 Guillain-Barré syndrome
Cases are classified into levels 1, 2 or 3 of diagnostic certainty. Level 3 of diagnostic certainty requires three groups of clinical symptoms or signs and the absence of an alternative diagnosis. Level 2 requires level 3 plus CSF white blood cell ,50 cells/microliter or, if no CSF was collected then electrophysiological findings consistent with Guillain-Barré syndrome. Level 1 requires level 3 plus electrophysiological findings consistent with Guillain-Barré syndrome and CSF cytoalbuminologic dissociation ( Figure 7 ). 
Figure 8 Anaphylaxis
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Figure 9 Anaphylaxis levels of diagnostic certainty
Anaphylaxis is then classified into Brighton Collaboration Levels 1, 2, and 3 of diagnostic certainty using the major criteria in Figure 8 and minor criteria in the case definition (Figure 9 ). 3 The next two figures (Figures 10 Laboratory diagnosis, and Figure 11 Other findings) are used to capture additional information about the case helpful in making an informed classification. Data entry in these sections was set up to be dynamic to reflect the wide variety of potential entry types.
Figure 10 Laboratory tests for the diagnosis of yellow fever and other infectious diseases
Laboratory diagnosis of yellow fever and other infections: fields include eleven yellow fever specific tests, 22 tests for other infectious diseases, and free entry of other laboratory tests with values and units ( Figure 10 ). 
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Figure 11 Other findings
Fields include past medical history, other vaccines received, and current medications ( Figure 11 ). 
Figures 12 and 13 Decision flow tree for Brighton Collaboration yellow fever vaccine-associated decisions
Conclusion
Researchers can modify the ACCESS database to assess other vaccines using Panel 1, modifying Panels 10-12, and adding panels for the criteria to assess other vaccines. The database is intended to be adapted by researchers either who wish to assess published cases of potential SAEs attributed to other vaccines, or are in the field and wish to assess reported SAEs during vaccination campaigns (they could modify or simplify the panels in this database). In the case of published cases data integrity should have been assured by the publishing editors. In the case of databases used during vaccine campaigns the researchers would need to code and encrypt the basic identifying data for cases.
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